UBS raised the firm’s price target on Johnson & Johnson to $190 from $180 and keeps a Buy rating on the shares. Johnson & Johnson is well-positioned to deliver upside into the second half following the strong beat and raise quarter, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $167 from $164 at Guggenheim
- Johnson & Johnson granted FDA Priority Review for TAR-200 NDA
- Johnson & Johnson price target raised to $175 from $161 at BofA
- Johnson & Johnson price target raised to $172 from $159 at Bernstein
- Johnson & Johnson price target raised to $176 from $165 at Barclays